Wegovy (semaglutide 2.4 mg) is a once-weekly injectable medicine licensed in the UK for weight management in adults with obesity or overweight with at least one related health condition
A higher dose of semaglutide does not automatically mean more weight loss, as the dose-response relationship is more nuanced than that
[80] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial
Two excellent examples of reputable companies are GenSci, the maker of Jintropin, and AnkeBio, the maker of Ansomone
However, both medications have similar safety concerns in pregnancy and should be used with caution when planning for conception
( a-b ) Representative histological images of in situ hybridization for DAPI (grey), Cre (red), Glp1r (cyan), and Gnas (green) from a ( a ) wildtype (n = 3 mice) or ( b ) Gnas fl/fl (n = 3 mice) mouse